Latest Videos Archives

HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer

Posted by Celestia S. Higano, MD | Jun 2020

Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The Hero trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. Following this in an interview with Celestia S. Higano, MD, section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, about the study’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.

Multiparametric MRI for the Detection of Clinically Significant Prostate Cancer

Posted by Jelle Barentsz, MD, PhD | Jun 2020

Jelle Barentsz, MD, PhD, Professor of Radiology at the Nijmegen Medical Center of Radboud University in Nijmegen, The Netherlands, discusses the ins and outs of diagnosing clinically significant prostate cancer (csPC) using mpMRI. He goes on to discuss how to improve the diagnostic accuracy of mpMRI, including optimizing image acquisition, use of training sessions to refine the radiologist’s expertise and interpretation of results, as well as how to reduce systematic and random error associated with MRI-directed biopsy.

The Capacity of MRI to Predict Extracapsular Disease

Posted by Jelle Barentsz, MD, PhD | Jun 2020

Jelle Barentsz, MD, PhD, Professor of Radiology at the Nijmegen Medical Center of Radboud University in Nijmegen, The Netherlands, discusses the capacity of MRIs to predict extracapsular disease. He notes that this is not a perfect technology and it is not possible to predict with one hundred percent accuracy, but he emphasizes how it can be useful for staging. He also discusses when it is necessary to wait and how long to wait after a biopsy for a staging MRI. Lastly, he covers situations where it is not necessary to wait for an MRI.

Vetting Your Telemedicine Vendor

Posted by Neil H. Baum, MD | May 2020

Neil H. Baum, MD, clinical professor of urology at Tulane Medical School in New Orleans, Louisiana, discusses how to choose the best telemedicine vendor for your practice. He goes over important questions to ask vendors before getting into business with them as well as the first steps for setting up. According to Dr. Baum, it is also imperative that a vendor has experience working in the urology field so that they are familiar with federal and state regulations. He also goes over technology concerns that can affect how well a certain platform will work for different doctors and for patients. He emphasizes the importance of privacy and security, as well as several concerns about how the system actually works and the support they offer.

Innovation in the Treatment of Male Urinary Incontinence

Posted by David Utz | May 2020

Culley C. Carson III, MD, Emeritus Rhodes Distinguished Professor in the Department of Urology at the University of North Carolina School of Medicine, discusses innovations in the treatment of male urinary incontinence. He outlines different treatments and their various pros and cons, including some cutting-edge technology that is not yet available in the US. He also goes over innovations, which still need to be made in order to further improve certain technologies like the artificial urinary sphincter. He highlights how important it is to come up with a more cost-effective model because, currently, artificial urinary sphincters are extremely expensive. There are also several significant causes of revision surgery for artificial urinary sphincters, demonstrating the need for further innovation. Dr. Carson also emphasizes the importance of customizing the pumps to individual patients, and goes over current research intended to improve patient outcomes.